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Abstract 
 
The global incidence of skin cancer and actinic keratosis (AK) has increased dramatically in 
recent years. Although many tumours are treated with surgery or radiotherapy topical therapy 
has a place in the management of certain superficial skin neoplasms and AK. This review 
considers skin physiology, non-melanoma skin cancer (NMSC), the relationship between AK 
and skin cancer and drugs administered topically for these conditions. The dermal 
preparations for management of NMSC and AK are discussed in detail. Notably few studies 
have examined drug disposition in cancerous skin or in AK. Finally, recent novel approaches 
for targeting of drugs to skin neoplasms and AK are discussed.  
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Abstract 
 
The global incidence of skin cancer and actinic keratosis (AK) has increased 
dramatically in recent years. Although many tumours are treated with surgery or radiotherapy 
topical therapy has a place in the management of certain superficial skin neoplasms and AK. This 
review considers skin physiology, non-melanoma skin cancer (NMSC), the relationship between 
AK and skin cancer and drugs administered topically for these conditions. The dermal preparations 
for management of NMSC and AK are discussed in detail. Notably few studies have examined drug 
disposition in cancerous skin or in AK. Finally, recent novel approaches for targeting of drugs to 
skin neoplasms and AK are discussed.  
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1. Introduction  
Skin cancer is the most common cancer in Caucasian populations (Byrd-Miles et al., 
2007). Damage of skin cell deoxyribonucleic acid (DNA) by ultraviolet (UV) radiation followed by 
failure of DNA repair mechanisms is the primary cause of these neoplasms. In the early stages, skin 
cancers develop in the outer layers of the skin. If not treated, they may grow deeper into the skin 
with development of metastases (secondary malignant growths distant from the primary origin). An 
actinic keratosis (AK) or solar keratosis is a scaly or crusty growth on the skin indicative of 
sustained damage by the sun. AK may progress to invasive neoplasms and have been interpreted as 
the earliest sign of skin cancer (Ibrahim and Brown, 2009). Early diagnosis is critical for the 
effective prognosis and treatment of patients with skin cancer. However, anticancer drugs which are 
administered orally or by the intravenous route are associated with serious side effects especially 
when given systemically. Topical dosage forms deliver most of the drug locally with fewer side 
effects compared with other routes of administration.  
To date, a very limited number of molecules has been administered topically to skin 
cancer lesions or AK. This article provides a brief overview of skin physiology, describes the 
location and classes of skin cancers amenable to topical therapy and outlines the AK - skin cancer 
continuum. Surgery and chemotherapy are the definitive treatments for melanoma; therefore this 
type of cancer is only briefly reviewed here (Maverakis et al., 2014). Topical formulations are 
examined and, where available, skin penetration properties of the various drugs are detailed. New 
strategies for targeted drug delivery to skin cancers and AK are considered with an emphasis on 
studies conducted in vitro with porcine or human tissue, or in patients.  
 
2. Skin structure and physiology  
The various skin layers, appendages and cell subtypes are presented in this section as a prelude to 
discussion of the skin cancers most commonly reported, their causalities and location in the skin, 
which is detailed in the following section.  
2.1 Epidermis  
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The skin acts as an interface between the internal organs and the environment. It is the 
largest organ of the human body and accounts for 10% of anatomic weight. Structurally, the skin is 
a multi-lamellar organ and it is involved in several physiological functions. The three layers of the 
skin are the epidermis, dermis and subcutaneous tissue. The outermost lamina of the epidermis, the 
stratum corneum (SC) represents the major barrier. This unique membrane prevents excessive water 
loss and is the major route for the percutaneous absorption of exogenous material as reviewed in 
detail by Menon et al. (2012), and Baroni et al. (2012).  
The epidermis is a multi-layered structure whose thickness varies from 0.8 mm (on the 
palms and soles) to 0.06 mm (on the eyelids). Histologically, the epidermis is further sub-divided 
into four different layers of cells (Figure 1). The cells (keratinocytes) that are present at the dermal-
epidermal junction form the stratum basale (or stratum germinativum). These cells contain nuclei, 
are columnar in shape and are anchored to the dermis via collagen fibres (Wertz and Downing, 
1989). This layer also contains other cells, namely melanocytes, Langerhans cells and Merkel cells 
(Benson, 2012).  Two billion melanocytes are distributed throughout the body with approximately 
1500 melanocytes per square millimetre in skin but this may vary with anatomic site (Halaban et al. 
2003). Melanocytes are triangular in shape and consist of a central cell body with a number of 
branches or dendrites (Figure 2).   
Two melanin pigments are synthesised in the melanocytes: eumelanin, a dark brown-
black insoluble polymer, and phaeomelanin, a light red-yellow sulphur containing soluble polymer 
(Ito and Wakamatsu, 2003). Melanin pigments are produced from tyrosine by an enzyme called 
tyrosinase through a series of oxidative steps and are stored in melanosomes which are specialised 
organelles present in melanocytes (Raposo and Marks, 2002). Melanosomes migrate to the 
neighbouring keratinocytes of the basal layer via the dendrites of the melanocytes (Figure 2). Along 
with keratinocytes, melanosomes also migrate towards the SC and finally disintegrate or eventually 
are shed from the surface of SC. Melanin protects the skin from UV-induced DNA-damage by 
directly absorbing UV photons and free radicals produced from the interaction of UV photons with 
cellular lipids (Park et al., 2009).  
Above the stratum basale 2 to 6 rows of cell layers form the stratum spinosum (prickle 
cell layer or squamous cell layer). As keratinocytes migrate upwards from the stratum basale, their 
shapes change from columnar to polygonal and their nuclei decrease in size. The stratum 
granulosum overlays the spinosum cell layer and consists of 1 to 3 layers of cells. In this layer 
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keratohyalin granules and membrane-coating granules are present and the latter are the precursors 
to the intercellular lipid lamellae of the SC. A separate layer, the stratum lucidum is present in the 
palm of the hand and sole of the foot. The cells of this layer are flat and compact and progress to 
become the anucleate and cornified dead cells of the SC (Benson, 2012).  
The SC is predominantly composed of keratin (70 – 80%) and lipid and consists of 10 
to 15 layers of flattened, keratinised dead cells (corneocytes). Most of the lipid content of the SC is 
present between the corneocytes (Elias et al., 1981). The thickness of this layer is only 10 to 20 μm 
when dry and it has been likened to a brick wall where the corneocytes are the „bricks‟ present in 
the „mortar‟ which represents the intercellular lipid matrix (Michaels et al., 1975). Desmosomes 
link corneocytes together, and a filamentous network of keratin is present in the cells which are 
surrounded by a protein-lipid rigid envelope (Figure 1). This envelope is highly resistant to external 
chemical assault and regulates the hydration between the intra- and extra-cellular environments of 
the corneocytes (Elias, 1988). The multiple lipid lamellae which occupy the intercellular space 
consist of ceramides (41%), cholesterol (27%), cholesterol esters (10%), cholesterol sulphate (2%) 
and free fatty acids (9%). Water is also present in the SC, mainly associated with keratin with 
smaller amounts in the polar head groups of intercellular spaces (Suhonen et al., 1999). Proteolytic 
and lipolytic enzymes are also present in the SC that perform a range of biochemical activities, such 
as lipid processing and desmosome breakdown (Menon et al., 2012). It is the unique composition 
and ultrastructure of the SC which is responsible for its excellent barrier properties (Potts and 
Francoeur, 1991).  
 
2.2 Dermis 
The dermis or corium is about 20 to 30 times thicker (3 to 5 mm) than the epidermis and 
consists of collagen fibrils and elastic connective tissues (Katz and Poulsen, 1971). Collagen is 
responsible for the strength of the skin and holding skin tissue together. Elastic connective tissue 
immersed in a semi-gel matrix of mucopolysaccharide provides flexibility. Cells present in the 
dermis include fibroblasts, mast cells, macrophages, lymphocytes and melanocytes. Blood vessels, 
nerves and skin appendages (sweat and sebaceous glands) are also present in this layer. Structurally, 
this layer does not offer the same resistance to drug penetration as the SC, however, reduced 
permeation of lipophilic drugs may be observed in this layer (Benson, 2012). Because of the rich 
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blood supply in the dermis, this layer regulates temperature and pressure, supplies nutrition and is 
involved in waste regulation of the skin (Katz and Poulsen, 1971). Various receptors such as 
thermoreceptors, nociceptors, and some mechanoreceptors are also present in this tissue. The 
mechanoreceptors consist of Meissner‟s corpuscles and Pacinian corpuscles which recognise touch 
and pressure, respectively (McGrath and Pope, 2008). 
2.3 Subcutaneous tissue (hypodermis) 
The subcutaneous tissue is a specialised layer of fat cells interconnected by collagen and 
elastin fibres. This layer produces and stores large quantities of fat. It also acts as a heat insulator, 
protects the body from mechanical shock and stores large quantities of calories (Wood and Bladon, 
1985) 
2.4 Skin appendages 
There are several appendages present in the dermis and epidermis of human skin, such as 
eccrine and apocrine sweat glands, sebaceous glands, hair follicles and nails. The eccrine sweat 
glands produce 99 to 99.5% water containing some electrolytes, with a pH of ~5. The glands 
primarily control the heat of the body. Apocrine sweat glands are distributed in the axillae, 
anogenital region and in the nipple area of the breast. The glands secrete milky or oily fluids. 
Sebaceous glands are mainly distributed on the face, forehead, anogenital surface, and chest and on 
the back of the body (400 - 900 glands/cm
2
). The glands secrete sebum which mainly protects and 
lubricates the skin. Hair follicles are present throughout the body except on the palms, soles and in 
some parts of the lips and sex organs (Katz and Poulsen, 1971). Hair and nails contain hard keratin 
with the latter being formed of protective plates of protein. The cells of the nail plate develop in the 
nail matrix and the nail plate grows at a rate of 0.1 mm/day (Walters et al., 2012).  
 
3. Skin cancers and AK  
Skin cancer is broadly classified into two types based on its origin: non-melanoma skin 
cancer (NMSC) and melanoma. General risk factors for development of skin cancer include (i) skin 
phototype (i.e., how skin responds to ultraviolet [UV] radiation, also known as Fitzpatrick skin 
type), (ii) excessive exposure to UV radiation, and (iii) immunosuppression (Murphy, 2009). AK is 
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recognised to exist in a continuum with NMSC, with 10% of AK lesions becoming cancerous if 
untreated (Fuchs and Marmur, 2007). 
 
3.1 Non-melanoma skin cancer (NMSC)  
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are classified as 
NMSCs. BCC and SCC develop in the basal and squamous (spinosum) layers of the epidermis, 
respectively (Wood and Bladon, 1985). BCC mainly occurs on the face and the back of the hands 
and most SCCs occur on the head and the neck. BCC grows slowly and spreads locally with little or 
no metastasis, however, SCC may progress to invasive SCC and there is a 2-6% risk of metastasis 
(Jerant et al., 2000; Motley et al., 2002).  
UV radiation is the primary cause of NMSC. The three regions of the UV spectrum are 
as follows: UV-A (320-400 nm), UV-B (280-320 nm) and UV-C (100-280 nm).  However, UV-C is 
largely attenuated or absorbed by atmospheric gases. UV-B is the most carcinogenic radiation and 
induces a tan in the skin but causes burning first. Long term exposure to UV-B results in photo-
aging and cancer. UV-A is less harmful to human skin compared with UV-B (Maddodi and 
Setaluri, 2008; Madan, 2009). Exposure to UV radiation produces specific mutations in 
keratinocytes which leads to NMSC. Cellular DNA absorbs UV-B photons and generates a number 
of photoproducts. UV-A indirectly damages DNA by producing reactive oxygen species. If the 
DNA damage is not repaired, this causes specific DNA mutations. Mutations arise primarily by 
substitution of a single cytosine (C) for a thymine (T) base and, to a lesser extent, by substitution of 
a double base CC for TT at pyrimidine sites (Ratner et al., 2001). Protection against DNA damage 
or mutation from UV radiation requires DNA repair mechanisms and the production of melanin. In 
human cells, DNA photoproducts are mainly eliminated by a nucleotide excision repair (NER) 
mechanism. With increasing age, the DNA repair mechanism is decreased and the incidence of 
NMSC is higher in older patients (Bath-Hextall et al., 2007). In addition, in some genetic disorders 
such as in xeroderma pigmentosum, because of the defects in the NER gene, the DNA 
photoproducts cannot be removed. In such genetic defects the risk of developing NMSC is high. 
Melanin produced from melanocytes migrates into the surrounding keratinocytes in the basal layer 
of the epidermis and normally provides protection against UV radiation. However, melanin cannot 
prevent DNA damage in the superficial layers as it is shed from the SC along with keratinocytes.  
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BCCs derive from the stratum basale, and may present as nodules or strands of cells 
(basaloids) which grow parallel to the epidermis. Nodular BCC is associated with well-defined 
“pearly” nodules and cell strands in the dermis. Superficial BCC presents as one or more 
erythematous lesions which are usually dry or scaly. Morpheaform or sclerosing BCC appears as 
thin strands of cells embedded in supporting tissue. Fibroepithelioma of Pinkus is a rare type of 
BCC found on the lower trunk or natal cleft; this presents as elongated strands of basaloids 
connected to overlying epidermis (McCormack et al., 1997; Goldenberg, 2010).  
SCCs present with many distinct subtypes and diverse presentations. The carcinoma 
itself consists of atypical keratinocytes which may be present in all layers of the epidermis. Cells 
may present with faulty cornification, pale or vacuolated cytoplasm and nuclei may be present in 
cells of the stratum corneum (parakeratosis). The atypical keratinocytes do not penetrate into the 
dermis. Invasive SCC tumours originate in the epidermis, infiltrate the dermis and present as nests, 
sheets and strands of atypical keratinocytes. Dyskeratosis (premature keratinisation in cells not in 
the outer layers) as well as parakeratosis may be present variably in the tumour. These neoplasms 
may be further sub-classified depending on the extent of differentiation or keratinisation. With 
increasing depth of penetration of the tumour the risk of metastatic spread increases significantly. 
The histological patterns of the various SCCs and BCCs are illustrated and described in greater 
detail by Goldenberg and colleagues (Goldenberg, 2010). Keratoacanthoma is a neoplasm that 
originates from the hair follicles and is generally treated as a SCC (Schwartz, 2004).  
 
3.2 Melanoma 
Melanoma is a tumour which arises from the melanocytes (Wood and Bladon, 1985). It 
is the most lethal type of skin cancer and, unlike NMSC, is more common in younger and middle-
aged patients (Jerant et al., 2000; Ries et al, 2000). Besides skin, melanoma can develop in the eyes 
and the mucous membranes of the vagina, anus, sinus and oropharynx but occurrence in these sites 
consists of only 5% of total melanomas (Kudchadkar and Weber, 2011). Cutaneous melanomas are 
classified as superficial spreading, lentigo maligna, nodular and acral lentiginous.  It is not always 
possible to classify malignant melanomas (MMs) because of their varying presentations (Markovic 
et al., 2007).  
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The main risk factor for melanoma is UV-B radiation, especially intermittent intense 
UV exposure. Individuals who burn but sometimes tan (Skin phototypes I and II) with light-hair are 
at greatest risk of melanoma (Bataille, 2013). There is a clear genetic association in a number of 
melanoma cases (Meyer and Zone, 1994). Mutations in the cyclin-dependent kinase inhibitor 2A 
(CDKN2A) and cyclin-dependent kinase 4 (CDK4) genes have been observed in families with 
inherited melanoma. Other genes have also been linked to a predisposition to melanoma (Aoude et 
al., 2015). Mutations in the B Rapidly Accelerating Fibrosarcoma (BRAF) gene are associated with 
40-50% of melanoma cases (Lee et al., 2011a). This gene encodes for the BRAF protein which 
plays an important role in regulating pathways involved in cell signalling, production and secretion. 
Mutations in the Neuroblastoma Rat Sarcoma (NRAS) gene have been found in 15-20% of 
metastatic melanoma patients; this mutation achieves similar downstream effects as the BRAF 
mutation (Curtin et al., 2005; Lovly et al., 2012).  
All primary MMs begin as a proliferation of melanocytes at the dermo-epidermal 
junction. MM becomes invasive as atypical melanocytes move into the dermis either individually or 
as aggregates. Some subtypes present with atypical melanocytes confined to the epidermis. 
Superficial spreading MM presents with atypical melanocytes at all levels of the epidermis with 
significant upward invasion of the epidermis. In the dermis atypical melanocytes may be present as 
individual cells or nests; melanocytes show failure of maturation with descent into the dermis. 
Melanoma progress has been classified as follows: Stage I and II are localised tumours which are 
restricted to the skin; Stage III is characterised by the involvement of lymph nodes and /or 
metastases and in Stage IV melanoma the metastases have spread to other organs or distant lymph 
nodes (Balch et al., 2009).  
 
3.3 Actinic keratosis (AK) 
AK also known as solar keratosis has been described as the earlier stage of SCC in situ 
(McGuire et al., 2000). AK is an important marker of increased risk for invasive SCC; both AK and 
SCC share genetic tumour markers and the same p53 gene (tumour suppressor gene) mutations 
(Cockerell, 2000). AK develops into SCC in several steps as shown in Figure 3. AK begins with 
DNA damage and mutations induced by UV radiation. The SCC development process starts with 
the development of a „hot spot‟ or aggregation of small, microscopic transformed cells. Over time, 
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the aggregates form keratinocytes and show features of atypia and pleomorphism. Depending on the 
patient‟s immune response, the lesions may remain unchanged or grow and extend into the dermis. 
Once the tumour cells are present in the dermis, it is termed SCC and subsequently tumour cells 
may become metastatic (Cockerell, 2000). AK lesions may present as dry, scaly patches appearing 
as pink, red or brown in colour and varying in size. Yellowing and thickening of the dermis (solar 
elastosis) is almost always present, and there may also be infiltration of lymphocytes and plasma 
cells (Röwert-Huber et al., 2007).  Hypertrophic keratoses are a subtype of AK and present as thick 
and scaly plaques; they may also present with conical growths or “horns”.  
AK has been classified into three types based on the extent of atypical keratinocytes in 
the epidermis (Röwert-Huber et al., 2007). Grade 1: Atypical keratinocytes are found above and in 
the stratum basale layer, and may occupy the lower one third of the epidermis; irregularities are 
present in nuclei. Grade 2: Atypical keratinocytes are present in the lower two-thirds of the 
epidermis alternating with zones of normal epidermis; buds of keratinocytes may be found in the 
upper dermis. Grade 3: Atypical keratinocytes are present in more than two thirds of the epidermis 
including the epitheliae of hair follicles; keratinocyte buds may be present in the dermis. 
 
3.4 Kaposi‟s sarcoma 
Kaposi‟s sarcoma (KS) is a systemic disease caused by human herpes virus 8 (HHV 8). 
The condition presents with skin lesions, and there may or not be visceral involvement. There are 
four clinical subtypes: classic, endemic, immunosuppression-associated and AIDS-related. KS skin 
lesions vary in colour, are raised and generally appear on the lower limbs, genitalia, back, face and 
mouth. Histologically, the tumour evolves from patch and plaque stages to become nodular 
(Ackerman, 1985).  
 
4.  Treatment of skin cancer and AK 
Local treatment of NMSC is determined based on the type, size, location of the lesion 
and patient age. Radiotherapy and surgery are the main treatment strategies. Lymph node dissection 
is also considered for SCCs as these tend to be more aggressive and have a higher tendency to 
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develop metastasis (McGuire et al., 2009). Oral chemotherapy with retinoids and cisplatin, 
photodynamic therapy, topical chemotherapy with retinoids, flurouracil (FU), diclofenac sodium 
and imiquimod, and laser surgery are also used occasionally (Telfer et al., 2008; Kudchadkar and 
Weber, 2011). Table 1 summarises the drugs currently used for topical therapy which are discussed 
in more detail in later sections.  
Depending on the stage of the cancer, melanoma may be treated by surgery, 
immunotherapy, targeted therapy, chemotherapy and radiotherapy. Surgery is the treatment option 
for primary melanoma. To boost the patient‟s immune response, an immunomodulator may be used, 
such as ipilimumab, cytokines (interferon-alpha, interleukin-II) or the Bacillus Calmette-Guérin 
(BCG) vaccine. Imiquimod cream may be used to stimulate the local immune response in early 
stage melanoma patients. Vemurafenib and dabrafenib, given orally, are BRAF kinase inhibitors 
and are used for late stage or advanced melanoma. Trametinib and selumetenib, also given orally, 
block a number of protein kinases of the signalling pathways activated in melanoma. Given 
systemically, dacarbazine and temozolomide (DNA methylating agents), cisplatin, carboplatin and 
carmustine (DNA cross-linking agents), and docetaxel, paclitaxel and vinblastine (tubulin 
inhibitors) are used as stand-alone chemotherapeutic agents for melanoma (Kudchadkar and Weber, 
2011; Homet and Ribas, 2014). The US Food and Drug Administration (FDA) has approved 
combination therapy (trametinib and dabrafenib) for advanced stage melanomas which cannot be 
removed by surgery and which have spread to the other sites of the body. Most recently a 
monoclonal antibody, nivolumab, was approved for advanced unresectable or metastatic melanoma; 
this is administered via intravenous infusion  (www.fda.gov).  
There are two types of treatment of AK: lesion- and field-directed. Lesion-directed 
treatment is suitable for treating single lesions found in grade 3 AK. In field-directed treatment, 
instead of single lesions, the entire field (containing ≥10 AK lesions) is treated. Lesion-directed 
treatment includes cryosurgery, laser and curettage. Field-directed treatment includes photodynamic 
therapy, and topical chemo- and immunotherapy. FU, diclofenac sodium, imiquimod and ingenol 
mebutate have shown efficacy in the treatment of AK (see Section 5). Electrodessication and 
curettage is more commonly used in the USA for treatment of AK (de Berker et al., 2007; Zalaudek 
et al., 2014).  
AIDS related KS is very effectively managed with systemic highly active antiretroviral 
therapy (HAART). Where there are only limited lesions and no involvement of internal organs, 
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topical treatment with alitretinoin is considered (Cheng et al., 2008). For classic KS, radiotherapy is 
usually used although small lesions may be removed using cryotherapy and surgery. A combination 
of radiotherapy and chemotherapy is used to treat endemic KS. For those patients where KS is 
associated with immunosuppression, the medication regime may be altered to reduce 
immunosuppressant dose; if this is not effective then radiotherapy or chemotherapy are used 
(Antman and Chang, 2000).  
 
5. Drugs currently used for topical treatment of skin cancer and AK  
To date topical chemotherapy and immunotherapy have been used for the treatment of 
BCC and AK, and for limited cases of KS as noted above. Topical treatment is considered where 
the tumours are present in the top layers of the skin and also for palliative treatment. Drugs 
currently in use (Table 1, Figure 4) and preparations available (Table 2) are discussed in more detail 
below. A discussion of Photodynamic Therapy (PDT) is not included here as it requires light 
activation of a photosensitiser molecule; detailed reviews have recently been published elsewhere 
describing the treatment of AK with PDT (Christensen, 2014; Wiegell, 2015). For most topical 
actives, effective clearance of AK lesions involves tissue inflammation, necrosis, and skin 
discomfort; ulceration and crusting are also common. This section reviews topical therapies which 
are currently available as well as novel approaches to enhance skin delivery of these molecules. The 
physicochemical properties of molecules currently in use are summarised in Table 1. It is 
interesting to note that these are low molecular weight compounds with limited or no aqueous 
solubility. Although FU and diclofenac sodium are relatively more hydrophilic than the other 
molecules in Table 1 they are clearly capable of permeating intact as well as diseased skin. 
Compounds with balanced Log P values and MW < 500 are typically considered good candidates 
for (trans)dermal delivery in normal skin. Effective permeation of normal skin would appear to be a 
reasonable requirement for any new drug considered for topical management of cancer or AK. As 
the disease state is treated the barrier function is restored and treatment to full recovery will require 
that the active is able to permeate normal tissue.  
 
5.1 Diclofenac sodium 
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Diclofenac has been used (as the sodium salt) for topical treatment of AK since the 
1990s (Rivers and McLean, 1997). The rationale for the use of this non-steroidal anti-inflammatory 
drug is the over expression of the cycloxygenase-2 enzyme in AK and SCC compared with normal 
cells (Buckman et al., 1998). In studies with SCC cell cultures, the commercial preparation, 
Solaraze™, when diluted to 0.2-0.3% was observed to promote apoptosis in certain sensitive cell 
lines (Fecker et al. 2010). Although sodium hyaluronate is included in the commercial gel 
formulation (Solaraze®), the precise function of this component remains unclear (Table 2). 
Systemic absorption of diclofenac from Solaraze™ has been reported but comparator studies with 
other diclofenac formulations have not been conducted (MHRA, 2010). Published clinical studies 
have focussed on the cure rates for the formulation as well as tolerability (Martin and Stockfleth, 
2012). Compared with other topical actives for AK, the dermatological side-effects for topical 
diclofenac are far less severe. Skin disposition and systemic absorption of diclofenac following 
application of Solaraze™ to AK lesions does not appear to have been investigated. However, given 
the long treatment times (Table 2), it may be beneficial to explore other strategies for the topical 
delivery of diclofenac to AK. Goh and Lane (2014) have recently reviewed the skin penetration 
characteristics of diclofenac and its salts, as well as the diverse formulation approaches investigated 
for topical delivery of the molecule in other therapeutic applications. The various methods explored 
to promote enhanced permeation of diclofenac include prodrugs, novel salt forms, supersaturation, 
use of skin penetration enhancers, microemulsions, lipid vesicles (including liposomes, 
Transferosomes™, lipid bicelles), solid lipid nanoparticles, liquid crystalline mesophases, 
cyclodextrins, nanosuspensions, films, patches, iontophoresis, laser microporation, ultrasound. For 
the chemical permeation strategies explored infinite doses of test formulations have largely been 
explored rather than finite doses thus there is considerable scope for further investigation with these 
methods. Microneedle (MN) mediated delivery of NSAIDs has recently been reported (McCrudden 
et al., 2014); this approach should allow higher drug loadings to be achieved in lesions and may 
also increase the number of candidate NSAIDs for topical AK treatment (McCrudden et al., 2014).  
 
5.2 Fluorouracil (FU) 
FU also known as 5-Fluorouracil (Figure 4) is approved for the topical treatment of AK, 
superficial BCC and Bowen‟s disease. The potential of FU in the management of AK emerged in 
the 1960s, with lesions disappearing in patients receiving systemic FU for other cancers (Falkson 
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and Schulze, 1962). FU inhibits the enzyme responsible for synthesis of thymidine, one of the 
pyrimidine nucleosides of DNA. FU is only sparingly soluble in water (Moffat et al., 2004), and the 
physicochemical properties of the molecule are detailed in Table 1. Originally FU was formulated 
in hydrophilic petrolatum (Dillaha et al., 1963; 1965) or simple propylene glycol gel vehicles for 
topical application (Lorenzetti, 1979). Creams and solutions are currently available in a range of 
strengths (Table 2) with all formulations containing skin penetration enhancers. Only the 5% 
preparations are used in the treatment of BCCs. One product (Actikerall®) for the treatment of AK 
also contains the keratolytic agent salicylic acid, as well as the penetration enhancer dimethyl 
sulphoxide.  
Permeation of FU has been studied in vitro using porcine skin (Gao and Singh, 1997, 
1998; Venuganti and Perumal, 2008, 2009; Hoppel et al., 2014) and human skin (Mollgaard et al., 
1982; Bond and Barry, 1988; Goodman and Barry, 1988; Aungst et al., 1990; Levy et al., 2001; 
Singh et al., 2005; Copoví et al., 2006; Wiechers et al., 2012; Mutalik et al., 2014). Most of these 
studies were performed under infinite dose conditions, thus findings are not easily extrapolated to 
typical amounts of FU applied by patients. Levy et al. (2001a) compared the in vitro skin 
permeation of three “microsponge” or microsphere-based formulations containing 0.5% FU with 
Efudex cream (5% FU) using human cadaver skin. Formulations were dosed at ~10 mg/cm
2
, and 
mass balance studies were also conducted. All of the microsponge formulations deposited greater 
amounts of FU in the skin (86-92%) compared with the commercial formulation (54%).  
Dillaha et al. (1965) investigated the systemic absorption of FU in 39 patients following 
topical application to AK on the face, neck, hands or arms; a number of patients also had BCCs or 
SCCs. The FU was incorporated at 1%, 2% and 5% in hydrophilic petrolatum, and approximately 
60g of the ointment was applied to lesions over a two to four week period. The 5% preparation 
proved to be more successful for AK than the lower strengths and was efficacious in treating the 
SCCs. The amounts of radiolabelled FU in urine were also measured following a two to three-week 
application of the highest strength preparation to the face. Urinary measurements were taken 12 h 
after application of 1 g of the ointment to the entire face (excluding eyelid area) and neck. The 
mean systemic absorption was calculated to be 6% of the applied dose. Erlanger et al. (1970) 
investigated the absorption of FU from a 5% ointment following application for 24 h to areas of 
healthy psoriatic skin, ulcerated skin or to a SCC. Amounts of FU applied ranged from 1.4 -1.8 
mg/cm
2
 and 
14
C-FU was measured in urine. For healthy skin the amount of FU excreted was 
reported to be 1.1% of the applied dose; corresponding values for psoriatic, ulcerated and SCC 
 15 
 
areas of skin were claimed to be 20%, 50% and 60%. However the amount of formulation applied 
appears to be extremely high (30 - 40 mg/cm
2
) and cannot be compared with the amounts typically 
applied to the skin; in addition, only six patients were included in the study. Senff and co-workers 
(1988) investigated FU absorption following application of a solution of FU (0.5 %) to warts in 6 
subjects; the treatment also contained DMSO and salicylic acid, and the warts were filed to enhance 
FU penetration. Plasma and urine analysis indicated that the mean amount of FU absorption was 
<0.1%. Dihydropyrimidine dehydrogenase (DPD) is responsible for catabolism of the pyrimidines, 
uracil and thymine, as well as FU. A rare case of FU toxicity has been reported in a patient with 
DPD deficiency following topical application of FU twice daily for one week in the management of 
BCC (Johnson et al., 1999). Levy et al. (2001b) reported the results of a study in AK patients who 
were randomised to apply either a 0.5% „microsponge‟ FU formulation daily or a 5% FU 
formulation twice daily for 28 days. FU was detected in the plasma of patients for both groups but 
in a higher proportion of the subjects who used the 5% FU; a similar trend was evident for urinary 
FU concentrations. Based on the limited number of subjects for whom FU urinary excretion values 
could be measured, systemic absorption was estimated as 0.6% for the 0.5% preparation and 2.4% 
for the 5% FU preparation.  
 
5.3 Imiquimod 
In 2004 a topical imiquimod cream (Aldara®) was approved by the FDA for the 
treatment of superficial BCC and AK. However, the cream has also been used in some other skin 
diseases such as Bowen‟s disease, lentigo melanoma, SCC and cutaneous melanoma metastasis 
(Taveira and Lopez, 2011). Imiquimod is an immunomodulator and it triggers a cellular immune 
response via toll-like receptor 7 (TLR7). This response results in up-regulation of a number of 
cytokines ultimately resulting in apoptosis of neoplastic cells (Sligh, 2014). Structurally, imiquimod 
is an imidazoquiniline (Figure 4), and it was originally developed as part of a programme to identify 
potential anti-viral agents (Schon and Schon, 2007). Chollet et al. (1999) have outlined the 
development steps leading to an effective topical formulation of imiquimod which is practically 
insoluble in water. Isostearic acid was selected as the primary solvent for the molecule, and the 
other formulation components of this oil-in-water cream include emulgents, viscosity modifiers and 
preservatives. A lower strength preparation (3.75% imiquimod, Zyclara®) is also available for 
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treatment of AK lesions on specific body sites. The lower strength preparation may be used daily, 
unlike Aldara®, and may also be applied over larger areas of skin (Table 2). 
Systemic levels of imiquimod have not been detected following application of Aldara® 
to genital/perianal areas for the treatment of warts but low levels of the drug were found in the urine 
(Owens et al., 1998). A bioadhesive patch formulation for delivery of imiquimod was designed and 
evaluated by Donnelly and co-workers (2006) using a poly(methyl vinyl ether-co-maleic anhydride) 
co-polymer. Drug loadings of 4.8, 9.5 and 12.5 mg/cm
2
 were prepared and evaluated for their 
release characteristics; however drug permeation characteristics in skin were not determined. De 
Paula et al. (2008) have reported the in vitro permeation of imiquimod in dermatomed porcine skin 
(500 m) in Franz cells from propylene glycol:water vehicles, with either urea or salicylic acid also 
included. Drug concentrations in the vehicles ranged from 50–750 g/ml with 1 ml of each 
formulation applied to an effective diffusional area of~0.8 cm
2
. Although the amount of drug which 
penetrated to the receptor compartment was much lower than the amounts retained in the skin, the 
authors did not determine the exact percentage of the dose which permeated. Pre-treatment of 
excised porcine skin with an erbium-doped yttrium aluminium garnet (Er:YAG) laser for enhanced 
delivery of imiquimod in vitro was reported by Lee et al. (2011b). Laser wavelength, pulse duration 
and energy applied were respectively, 2940 nm, 400 s at either 2 or 3 J/cm2. Maximum cumulative 
amounts of imiquimod which permeated in Franz cells after 48 h were ~20 g/cm2 for the laser 
treatment compared with <1 g/cm2 for the control. Control values are consistent with the data 
reported in the earlier study of De Paula et al. (2008). However, infinite dose conditions were 
employed (500 l of a 0.1% w/v formulation applied to ~0.8 cm2 of tissue). Iontophoresis as a 
delivery modality for imiquimod is the subject of a published US Patent Application (US 
2010/0331812 A1), although only data for rat models are disclosed. Although coated MN have been 
investigated for co-delivery of imiquimod and the H1N1 subunit vaccine (Weldon et al., 2012), they 
do not appear to have been considered for targeting of imiquimod to AK or cancerous lesions.  
 
5.4 Ingenol mebutate 
Ingenol mebutate (IM) is a macrocyclic diterpene ester which was originally isolated 
from an indigenous Australian plant, Euphorbia peplus (Siller et al., 2009). The precise mechanism 
of action of IM is not known, however it promotes rapid lesion necrosis and neutrophil-mediated 
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cellular cytotoxicity (Rosen et al., 2012). Modulation of protein kinase C isoforms has also been 
observed in tumour cells in vitro (Kedei et al., 2004). Currently, gel formulations are available in 
two strengths for the treatment of AK, the lower for the face and the higher for the extremities 
(Table 2). Treatment is typically for three consecutive days which is much shorter when compared 
with other topical AK therapies.  
Erlendsson and co-authors (2015) have recently reported the effects of ablative laser 
treatment on IM disposition in porcine skin in vitro. Microscopic ablated areas were generated by 
application of either 11.2 or 128 mJ to excised areas of skin. Control and laser-treated skin samples 
were mounted in Franz cells of diffusion area 0.64 cm
2
, and the amount of formulation applied in 
the donor chamber was 10 L/cm2. Penetration of IM to the receptor fluid was not observed in the 
intact skin samples but up to 21% of the applied dose was determined in the laser treated skin 
samples. Mass balance studies indicated that 57% of the applied dose remained in or on the skin at 
the end of the permeation experiment; for laser treated skin the maximal values in epidermis and 
dermis, respectively, were 62% and 18% of the applied dose. The presence of isopropyl alcohol in 
the IM formulation is surprising as it is likely to exacerbate the skin irritation associated with tissue 
necrosis.   
 
5.5 Topical retinoids 
 The effects of Vitamin A analogues (retinoids) on hyperkeratinisation, inflammation and 
immunomodulation following topical or oral application were demonstrated more than three 
decades ago (Elias and Williams, 1981). Retinoids work by interacting with retinoic acid receptors 
(RARs) or retinoic X receptors (RXRs) and activating genes that contain retinoic acid response 
elements (RAREs) or retinoic X response elements (RXREs). Effects on gene expression are also 
possible by inhibition of specific transcription factors (Michel et al., 1998).. First generation 
retinoids evaluated for topical treatment of AK include tretinoin (all trans-retinoic acid) and 
isotretinoin (13-cis-retinoic acid); the third geration retinoid, adapalene, has also been investigated 
(Kligman et al., 1991; Alirezai et al., 1994; Kang et al., 2003). Tretinoin and adapalene have also 
been used to treat AK or NMSC in conjunction with laser ablation therapy (Bercovitch, 1987; Kang 
et al., 2003; Prens et al., 2013; Pearce and Williford, 2014). Additionally, topical tretinoin has been 
investigated for its ability to reduce the risk of BCC and SCC but results to date do not support a 
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chemoprevention role (Weinstock et al., 2012). Overall evidence for efficacy of topical retinoids in 
the management of AK is lacking and thus they remain unapproved for therapy of this condition. 
Alitretinoin (9-cis-retinoic acid) is a first generation retinoid which activates both RARs and RXRs, 
ultimately resulting in modulation of genes responsible for cell proliferation and differentiation. It is 
used for the management of skin lesions in patients with AIDS-related KS, but not where systemic 
KS is indicated. Only one formulation of alitretinoin is currently available which is licensed both in 
Europe and the United States (Table 2).  
 
6. Summary and conclusions  
 The occurrence of skin cancer and AK is increasing in Caucasian populations. Topical therapy 
has an established role in the management of specific NMSCs and AK, particularly for improved 
skin appearance and quality of life for patients. To date, only a few low molecular weight actives 
have been available for direct application to these lesions. Surprisingly, some of the formulations 
currently available contain excipients which are likely to exacerbate the skin conditions being 
treated. Treatment times are overly long for other preparations, and there is scope to address this 
problem using alternative formulation strategies. The advent of skin poration approaches such as 
MN delivery clearly offers the possibility of more effective drug targeting to diseased skin but few 
studies have been carried out to date. Our understanding of the barrier properties of skin in these 
conditions remains limited despite the availability of advanced spectroscopic and biomechanical 
tools for skin examination. This, in part, reflects the inter-patient differences associated with skin 
diseases, and the variable clinical presentation of lesions. Finally, new chemical entities for the 
topical management of these skin conditions do not appear to be emerging despite the low number 
of actives currently in use.  
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Figure 1: Diagrammatic representation of: A. layers of human epidermis, B. ‘brick and mortar’ 
organisation of the SC, and C. organisation of aqueous and lipid domains in the intercellular bilayer region  
  
Melanocytes
Keratinocytes Melanin forming in 
melanosomes
Migration of 
melanosomes into the 
keratinocytes
Phaeomelanosomes
Eumelanosomes
 
Figure 2: Melanocytes and migration of melanosomes through the dendritic extensions to the surrounding 
keratinocytes (Adapted from Wood and Bladon, 1985) 
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Figure 3: Stages of development of SCC from AK and invasive SCC. (1) Atypical keratinocytes and (2) 
increased number of squamous cells containing enlarged, atypical and pleomorphic nuclei (adapted from 
Cockerell, 2000) 
                             
            5-Flurouracil                                         Diclofenac sodium                Imiquimod 
            
Ingenol mebutate       Alitretinoin 
Figure 4. Drugs currently used for topical treatment of skin cancer and AK. 
LIST OF TABLES 
 
Table 1: Physicochemical properties of drugs used for the topical treatment of skin 
cancer and AK 
 
Table 2: Topical preparations for the treatment of skin cancer and actinic keratosis 
 
 
  
Table(s)
Table 1: Physicochemical properties of drugs used for the topical treatment of skin 
cancer and AK 
 
Drug MW
a,c
 Log P
b
 Melting point
a,c,d 
Solubility
a,c,e
 pKa 
a,d,e,f
 
Alitretinoin 300.4 4.7 190-191°C Very slightly soluble in 
aqueous solution 
5.1 
Diclofenac sodium  318.1 - 283-285°C Sparingly soluble in water  4.2 
Fluorouracil 130.1 -0.8 282°C Sparingly soluble in water  8.0, 13.0 
Imiquimod 240.3 2.3 292-294°C Practically insoluble in 
water  
7.3 
Ingenol mebutate 430.5 2.0 154.1-156.8°C Practically insoluble in 
water  
12.7 
a
Moffat et al. (2004) 
b
Calculated from Molecular Modelling Pro.  
c
Merck Index (2012) 
d
Product Monograph, Leo Laboratories  
e
Chollet et al., 1999  
f
Product monograph, GSK 
  
Table 2: Topical preparations for the treatment of skin cancer and actinic keratosis 
Drug  Formulation  Indications and treatment 
regime 
Alitretinoin Panretin®  
0.1% alitretinoin, dehydrated alcohol, 
polyethylene glycol 400, hydroxypropyl 
cellulose, butylated hydroxytoluene 
AIDS related Kaposi’s 
sarcoma lesions, not 
indicated with systemic 
therapy of KS. 
Initially applied twice daily; 
may be increased up to four 
times daily. Duration of 
treatment dependent on 
lesion response.  
Diclofenac  
sodium  
Solaraze® 
3% diclofenac sodium, sodium 
hyaluronate, benzyl alcohol, macrogol 
monomethyl ether 350, purified water 
Actinic keratosis. 
Applied twice daily for up 
to 90 days.  
Fluorouracil 
(5-FU)  
Carac® cream 
0.5 % fluorouracil, Microsponge® 
[methyl methacrylate / glycol 
dimethacrylate cross polymer and 
dimethicone],  Carbomer 940, 
dimethicone, glycerin, methyl gluceth-20, 
methyl methacrylate / glycol 
dimethacrylate crosspolymer, 
methylparaben, octyl hydroxy stearate, 
polyethylene glycol 400, polysorbate 80, 
propylene glycol, propylparaben, purified 
water, sorbitan monooleate, stearic acid, 
trolamine 
 
Efudex® cream 
5% fluorouracil, stearyl alcohol, white 
soft paraffin, polysorbate 60, propylene 
glycol, methyl parahydroxybenzoate, 
propyl parahydroxybenzoate, purified 
water 
 
Efudex® solution 
2% or 5% fluorouracil, propylene glycol, 
tris (hydroxymethyl) aminomethane, 
hydroxypropyl cellulose, methyl 
parahydroxybenzoate, propyl 
parahydroxybenzoate, disodium edetate 
 
Fluoroplex® 
1% fluorouracil, benzyl alcohol, 
emulsifying wax, isopropyl myristate, 
mineral oil, purified water, sodium 
hydroxide  
Actinic keratosis.  
Applied once daily up to 4 
weeks. 
 
 
 
 
 
 
 
 
 
 
 
Actinic keratosis.  
Bowen's disease; 
superficial basal-cell 
carcinoma, 
keratoacanthoma. 
Applied once or twice daily 
for 4 weeks or longer.  
 
 
 
 
 
 
 
Actinic keratosis. 
Applied twice daily for up 
to 6 weeks. Increased 
frequency of application 
and longer duration of 
treatment if lesions not on 
head or neck.  
Fluorouracil, 
salicylic acid 
Actikerall®  
0.5% fluorouracil and 10% salicylic acid, 
dimethyl sulfoxide, ethanol, ethyl acetate, 
pyroxyline, poly(butyl methacrylate, 
methyl methacrylate) 
Actinic keratosis. Palpable 
and/or thick, hypertrophic 
lesions.  
Applied daily for up to 12 
weeks. Applied less 
frequently to areas of skin 
with thin epidermis or if 
severe side effects occur. 
Imiquimod Aldara®  
5% imiquimod, isostearic acid, benzyl 
alcohol, cetyl alcohol, stearyl alcohol, 
white soft paraffin, polysorbate 60, 
sorbitan stearate, glycerol, methyl 
hydroxybenzoate, propyl 
hydroxybenzoate, xanthan gum, purified 
water 
 
 
 
 
 
 
 
Zyclara® cream 
2.5% or 3.75% imiquimod, isostearic 
acid, benzyl alcohol, cetyl alcohol, 
stearyl alcohol, white soft paraffin, 
polysorbate 60, sorbitan stearate, 
glycerol, methyl hydroxybenzoate, propyl 
hydroxybenzoate, xanthan gum, purified 
water 
Actinic keratosis.  
Applied twice weekly, 
application site washed 
after 8 hours; treatment for 
up to 16 weeks. 
Superficial basal cell 
carcinoma. 
Applied five times per week 
for up to 6 weeks, 
application site washed 
after 8 hours. Applied to 
tumour and to 1 cm area 
surrounding tumour.  
 
 
Actinic keratosis. Non-
hypertrophic, non-
hyperkeratotic, visible or 
palpable lesions of head 
and face.  
Applied once daily for two 
treatment cycles each of 2 
weeks separated by 2 week 
washout. Application site 
washed after 8 hours. 
Ingenol 
mebutate  
Picato® 
150 g/g or 500 g/g of ingenol 
mebutate, isopropyl alcohol, 
hydroxyethylcellulose, citric acid 
monohydrate, sodium citrate, benzyl 
alcohol, purified water 
Actinic keratosis. Non-
hyperkeratotic, non-
hypertrophic lesions.  
Apply one tube daily for 
three days if lesions on face 
and scalp; apply one tube 
daily for two days if lesions 
on trunk and extremities. 
No washing or touching 
application site for 6 hours 
after application 
 
